+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Schizophrenia Drugs Market, By Therapeutic Class, By Treatment, By Distribution Channel & By Region- Forecast and Analysis 2022-2028

  • PDF Icon

    Report

  • 127 Pages
  • October 2022
  • Region: Global
  • SkyQuest Technology Consulting
  • ID: 5675610
The Global Schizophrenia Drugs Market was valued at USD 7.70 billion in 2021, and it is expected to reach a value of USD 10.50 billion by 2028, at a CAGR of 4.50% over the forecast period (2022 - 2028).

Schizophrenia is a major disorder of the categories of psychotic disorders, a type mental illness that impair a person's capacity for proper behaviour, rational thought, and good judgement. Patients with schizophrenia are two to three times more likely to die young than the overall population. Schizophrenia is frequently accompanied with severe suffering and impairment in key areas of one's life, such as those relating to the self, family, the community, education, employment, and others. Schizophrenia is a contributing factor in physical conditions such cardiovascular, metabolic, and recurrent infectious disease. It does not occur as frequently as many other mental illnesses.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Schizophrenia Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The Global schizophrenia drug market is segmented based on therapeutic class, treatment, distribution channel, and Region. Based on the therapeutic class the Global schizophrenia drugs market is segmented as Second Generation, Third Generation, and Others. Based on treatment, the Global schizophrenia drugs Market is segmented as Oral and Injectable. Based on the distribution channel, the Global schizophrenia drugs Market is segmented as Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. Based on Region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Driver

An increase in the number of patients undergoing treatment and a rising demand for better healthcare infrastructure are expected to boost the market. Governments from various countries have collaborated successfully with numerous institutions in recent years to improve the safety of people with schizophrenia. The market under consideration is growing as a result of the rising number of illnesses and the rising demand for effective disease management.

Restraint

Lack of adequate knowledge about the risk of mental health difficulties in developing countries is a hurdle for the market. Due to a lack of suitable sources, it is challenging to raise awareness of effective treatments among the public and attract their attention. The market is being badly impacted by this reason.

Market Trend

Formerly believed to be caused by high levels of presynaptic dopamine in certain regions of the brain, the mechanisms underlying schizophrenia are now understood to involve structural and chemical abnormalities throughout brain circuits. In order to find safer and more effective medications to treat schizophrenia and psychosis, drug development efforts have focused on new targets such trace amine-associated receptors (TAARs), muscarinic receptors, and seroton
Frequently Asked Questions about the Global Schizophrenia Drugs Market

What is the estimated value of the Global Schizophrenia Drugs Market?

The Global Schizophrenia Drugs Market was estimated to be valued at $7.7 Billion in 2021.

What is the growth rate of the Global Schizophrenia Drugs Market?

The growth rate of the Global Schizophrenia Drugs Market is 4.5%, with an estimated value of $10.5 Billion by 2028.

What is the forecasted size of the Global Schizophrenia Drugs Market?

The Global Schizophrenia Drugs Market is estimated to be worth $10.5 Billion by 2028.

Who are the key companies in the Global Schizophrenia Drugs Market?

Key companies in the Global Schizophrenia Drugs Market include H. Lundbeck A/S (Denmark), Otsuka Pharmaceutical Co., Ltd. (Japan), Janssen Pharmaceuticals, Inc. (Belgium), Eli Lilly and Company (US), AstraZeneca (UK), ALLERGAN (Ireland), Vanda Pharmaceuticals Inc. (US), Sumitomo Dainippon Pharma Co., Ltd. (Japan) and Bristol.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • H. Lundbeck A/S (Denmark)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Janssen Pharmaceuticals, Inc. (Belgium)
  • Eli Lilly and Company (US)
  • AstraZeneca (UK)
  • ALLERGAN (Ireland)
  • Vanda Pharmaceuticals Inc. (US)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Alkermes plc (Ireland)
  • Bristol-Myers Squibb Company (US)